1 results
Approved WMOCompleted
The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat- to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular…